Improving dialysis, improving patient care
M3Nephron B.V. is founded in 2025 in cooperation with Twente University, the Netherlands to further develop the innovative mixed matrix membranes and prepare for commercialization. The company has a strong patent portfolio for the development and commercialization of mixed matrix membranes in current haemodialysis treatments and also for future portable and wearable devices. The feasibility studies of the Mixed Matrix Membranes first product version are nearly finished and M3Nephron aims to market launch in 2029. Meanwhile we are preparing for clinical validations, CE-marking and FDA approval with our development partners.
